Drugs · acquisition-cost intelligence
Novolin R
Human Insulin· ingredient insulin, regular, humanInsulins and analogues for inhalation· INSULIN HUMAN 100 [iU]/mL
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per ML
$5.22
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per ML — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other insulin, regular, human products, cheapest acquisition cost first. Per ML — confirm strength/form equivalence before switching.
| Product | NADAC / ML | vs this |
|---|---|---|
| Humulin R | $4.27 | −$0.95650 |
| AFREZZA | $15.65 | +$10.43 |
| Humulin R U-500 | $91.64 | +$86.42 |
Medicare Part D coverage · CY2026
On 298 plan formularies · typical tier 3
Prior auth 21% · Step therapy 0% · Quantity limit 36% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.